Patent ID: 6841548

Claim:
A method of treating a patient, comprising the steps of: orally administering a pharmaceutical preparation to a patient requiring reduced estrogenic effects in their liver, the pharmaceutical preparation containing estra-1,3,5(10)-triene derivatives as active ingredients of the general formula I wherein R is an R1R2N group, R1 and R2 are independent of each other and represent a hydrogen atom, R3 is a hydrogen atom, a hydroxy group, or an alkoxy group containing 1 to 5 C atoms, R4 is a hydrogen atom or a C1-C5 alkyl radical, R5 is a hydrogen atom, a hydroxy group, an esterified hydroxy group, a haloalkyl or alkoxy group containing 1 to 5 C atoms, R6 and R7 are hydrogen atoms, or together form a methylene group, R8, R9 and R10 are independent of each other and represent a hydrogen atom or hydroxy group, with ring B optionally containing one or two double bonds or, optionally, R9 and R10 together forming an oxygen atom, or R6 and R9 representing a vinylene or ethylene group; and using the prepared pharmaceutical preparations for at least one of (a) contraception, (b) treatment of prostatic carcinomas, and (c) hormone replacement therapy, said pharmaceutical preparations having reduced estrogenic effects in the liver of a patient in which they are being used as compared to natural and synthetic estrogens.